322 related articles for article (PubMed ID: 36440195)
1. Endocrine and paracrine characteristics of neuroendocrine prostate cancer.
Arman T; Nelson PS
Front Endocrinol (Lausanne); 2022; 13():1012005. PubMed ID: 36440195
[TBL] [Abstract][Full Text] [Related]
2. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
3. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
[TBL] [Abstract][Full Text] [Related]
4. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications.
di Sant'Agnese PA
Cancer; 1992 Jul; 70(1 Suppl):254-68. PubMed ID: 1350941
[TBL] [Abstract][Full Text] [Related]
6. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors of the prostate.
Fine SW
Mod Pathol; 2018 Jan; 31(S1):S122-132. PubMed ID: 29297494
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
10. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
11. De novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2022 Sep; 127():112-122. PubMed ID: 35810832
[TBL] [Abstract][Full Text] [Related]
12. Reprint of: de novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
14. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
15. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
16. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.
Bonkhoff H; Stein U; Remberger K
Hum Pathol; 1995 Feb; 26(2):167-70. PubMed ID: 7532147
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.
Speights VO; Cohen MK; Riggs MW; Coffield KS; Keegan G; Arber DA
Br J Urol; 1997 Aug; 80(2):281-6. PubMed ID: 9284203
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
19. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
[No Abstract] [Full Text] [Related]
20. Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma.
Bellur S; Van der Kwast T; Mete O
Hum Pathol; 2019 Mar; 85():313-327. PubMed ID: 30481509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
